Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autonomix MedicalAMIX -12.48%15 EV-to-EBITDA is 0.45 as of Jul. 14, 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 511 Medical Devices & Instruments companies, Autonomix Medical ranks better than 98.04% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Autonomix Medical's enterprise value is $-7.56 Mil.
Autonomix Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-16.70 Mil. Therefore, Autonomix Medical's EV-to-EBITDA for today is 0.45.
The historical rank and industry rank for Autonomix Medical's EV-to-EBITDA or its related term are showing as below:
AMIX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.45
Current: 0.45
During the past 4 years, the highest EV-to-EBITDA of Autonomix Medical was 0.45. The lowest was 0.00. And the median was 0.00.
AMIX's EV-to-EBITDA is ranked better than 98.04% of 511
companies
in the Medical Devices & Instruments industry
Industry Median: 14.2
vs AMIX: 0.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Autonomix Medical (NAS:AMIX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Autonomix Medical's PE Ratio (TTM) for today is calculated as:
Autonomix Medical's share price for today is $5.765.
Autonomix Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.917.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Autonomix Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMIX vs BJDX, LUDG, ALURD: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Autonomix Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autonomix Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Autonomix Medical's EV-to-EBITDA falls into.
Autonomix Medical's current Enterprise Value is $-7.56 Mil.
Autonomix Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autonomix Medical (AMIX) has a EV-to-EBITDA of 0.45 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Autonomix Medical. According to the industry distribution chart, Autonomix Medical ranks #10 out of 511 companies in the Medical Devices & Instruments industry, placing it in the top 2%.
Is Autonomix Medical's EV-to-EBITDA too high?
Autonomix Medical's current EV-to-EBITDA is 0.45. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.20. Autonomix Medical's value of 0.45 is 96.8% below this industry median. Based on the distribution chart, Autonomix Medical ranks #10 out of 511 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's EV-to-EBITDA compare to BJDX and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #10 out of 511 companies for EV-to-EBITDA. This places Autonomix Medical in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.20. Autonomix Medical's value of 0.45 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.20, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autonomix Medical's current EV-to-EBITDA of 0.45 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Autonomix Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current EV-to-EBITDA is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current EV-to-EBITDA of 0.45. The current EV-to-EBITDA is 0.45 and 96.8% below the Medical Devices & Instruments industry median of 14.20. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current EV-to-EBITDA is 0.45 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score
Get the complete analysis for AMIX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMIX has been successfully added to your 
